Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
-
Rocket Pharmaceuticals, Inc. (RCKT)
Proxy statement
Current
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Current role
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Taysha Gene Therapies, Inc. (TSHA) | Chief Financial Officer | $473,331 | $2,146,964 |
| 2024 | Taysha Gene Therapies, Inc. (TSHA) | Chief Financial Officer | $455,126 | $2,518,777 |
| 2023 | Taysha Gene Therapies, Inc. (TSHA) | Chief Financial Officer | $413,751 | $975,401 |
| 2022 | Taysha Gene Therapies, Inc. (TSHA) | Chief Financial Officer | $401,700 | $1,201,823 |
| 2020 | Rocket Pharmaceuticals, Inc. (RCKT) | Senior Vice President – Finance and Principal Financial Officer | $197,230 | $634,250 |
| 2019 | Rocket Pharmaceuticals, Inc. (RCKT) | Senior Vice President – Finance and Principal Financial Officer | $54,545 | $2,051,457 |
Recent activity
Earnings-call appearances and filed executive appointments or departures, newest first.